<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00592943</url>
  </required_header>
  <id_info>
    <org_study_id>2007-P-001659</org_study_id>
    <nct_id>NCT00592943</nct_id>
  </id_info>
  <brief_title>PET Study Examining the Dopaminergic Activity of Armodafinil in Adults</brief_title>
  <official_title>A PET Study Examining the Dopaminergic Activity of Armodafinil in Adults</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aims of this study are 1) to document the Dopamine Transporter (DAT) receptor
      occupancy of armodafinil using positron emission tomography (PET) scanning with C-11
      altropane as the ligand and 2) to document the increased intrasynaptic dopamine produced by
      armodafinil using PET scanning with C-11 raclopride as the ligand. We hypothesize that DAT
      occupancy will be low with armodafinil; less than the DAT occupancy produced by therapeutic
      doses of methylphenidate. We also hypothesize that increases in intrasynaptic dopamine will
      be relatively low with armodafinil.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Modafinil produces a unique spectrum of pharmacological effects including enhanced vigilance,
      arousal, and wakefulness in human subjects (Bastuji and Jouvet 1988). The drug is widely used
      to treat narcolepsy (Banerjee, Vitiello et al. 2004), but is also effective in Attention
      Deficit Hyperactivity Disorder (ADHD) (Biederman, Swanson et al. 2005). Notwithstanding the
      expanding clinical indications for modafinil, the neurochemical mechanisms that produce
      therapeutic improvement remain unresolved. Pre-clinically, modafinil is a weak inhibitor of
      the DAT, and displays no affinity for dopamine receptor subtypes (Mignot, Nishino et al.
      1994). Further evidence supporting low dopaminergic activity is the low abuse potential of
      modafinil (Jasinski 2000). Various theories have been proposed as alternative modes of action
      including enhancement of glutamate release and inhibition of Gamma-aminobutyric acid (GABA)
      release in various brain regions (Ferraro, Antonelli et al. 1997; Ferraro, Antonelli et al.
      1997; Ferraro, Antonelli et al. 1999). However, the exact mechanisms of action of modafinil
      and the principle active metabolite, armodafinil, are unknown. Understanding these mechanisms
      of action is important in assessing the potential therapeutic role of armodafinil. We will
      test to see if there are differences in the degree of DAT occupancy and D2 binding of
      armodafinil compared with that of traditional stimulants.

      The main target of typical stimulants in the brain is the dopamine transporter (DAT) (Volkow,
      Wang et al. 1998). We have an exquisitely sensitive methodology to measure DAT occupancy
      using C-11 altropane and Positron Emission Tomography (PET) (Fischman, Bonab et al. 2001).
      Our group has previously documented the central nervous system pharmacokinetics of several
      psychiatric drugs (including methylphenidate) using similar techniques. (Christian, Livni et
      al. 1996; Fischman, Bonab et al. 1996; Fischman, Alpert et al. 1997; Salazar and Fischman
      1999; Fischman, Alpert et al. 2002; Spencer, Biederman et al. 2006).

      Increases in intrasynaptic (extracellular) dopamine concentrations associated with
      medications are routinely measured by changes in C-11 raclopride binding in PET scans. C-11
      raclopride binds to postsynaptic D-2 receptors. If the intrasynaptic concentration of
      dopamine increases, it competes with raclopride leading to a weaker signal (i.e. decreased
      raclopride binding to D-2 receptors). After administration of a stimulant, associated
      increases in intrasynaptic dopamine compete with C-11 raclopride binding in this manner
      (Volkow, Wang et al. 2002). By using this technology we can document the change in D-2
      binding in the intrasynaptic space achieved by armodafinil, and compare it to that achieved
      by a typical stimulant.

      To this end, using two PET ligands (C-11 altropane and C-11 raclopride), this protocol seeks
      to compare the DAT receptor occupancy and the increased intrasynaptic dopamine produced by
      armodafinil to previous studies of methylphenidate. This research will provide novel and
      unique information toward better understanding the mechanisms of action of armodafinil in
      comparison to those of typical stimulants.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">May 2010</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Armodafinil DAT Occupancy in Caudate</measure>
    <time_frame>DAT occupancy was measured using the PET scan at 1 hour and 2.5 hours after oral administration of 100mg or 250 mg Armodafinil</time_frame>
    <description>Subjects received each dose level (100 and 250 mg) of armodafinil, followed by PET scans, in an open-label protocol. Repeat PET scans, using [1 1 C]altropane, determined DAT occupancy at 1 hour and 2.5 hours postdose (compared with baseline).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (With Outlier)</measure>
    <time_frame>Extracellular DAT was measured using the PET scan at 2.5 hours after oral administration of 100mg or 250 mg Armodafinil on three different study visits</time_frame>
    <description>Each subject received each dose level (one dose per day of 100 or 250 mg) of armodafinil, followed by PET scans using [11C]raclopride, to determine the change in extracellular dopamine at 2.5 hours postdose.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (Without Outlier)</measure>
    <time_frame>Extracellular DAT was measured using the PET scan at 2.5 hours after oral administration of 100mg or 250 mg Armodafinil on three different study visits</time_frame>
    <description>Each subject received each dose level (one dose per day of 100 or 250 mg) of armodafinil, followed by PET scans using [11C]raclopride, to determine the change in extracellular dopamine at 2.5 hours postdose.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Armodafinil (100mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Armodafinil (250 mg)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>armodafinil</intervention_name>
    <description>tablet, taken by mouth, once each study day</description>
    <arm_group_label>Armodafinil (100mg)</arm_group_label>
    <arm_group_label>Armodafinil (250 mg)</arm_group_label>
    <other_name>Nuvigil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Signed written informed consent to participate in the study.

          2. Age: 18 - 35

          3. If female, non-pregnant, non-nursing with a negative serum pregnancy test and using an
             adequate form of birth control.

          4. Supine and standing blood pressure within the range 110/60 to 150/95 mmHg.

          5. Heart rate, after resting for 5 minutes, within the range 46-90 beats/min.

          6. Right-handed.

        Exclusion Criteria:

          1. Diagnosis of any psychotic disorder, bipolar disorder, severe depression, severe
             anxiety, or Autism.

             Subjects with mild mood, oppositional, conduct, and anxiety disorders may be permitted
             to participate if considered appropriate by the investigator.

          2. Scores of Baseline Scales:

             Hamilton Depression Scale &gt; 17 (out of a possible 67 on the 21-item scale)(Hamilton
             1960) Beck Depression Inventory &gt; 19 (out of a possible 63 on the 21-item scale)(Beck,
             Ward et al. 1961) Hamilton Anxiety Scale &gt; 21 (out of a possible 56 on the 14-item
             scale) (Hamilton 1959)

          3. Tics or Tourette's Syndrome.

          4. History of head trauma with loss of consciousness, organic brain disorders, seizures,
             or neurosurgical intervention.

          5. Any clinically significant chronic medical condition, in the judgment of the
             investigator.

          6. Mental impairment as evidenced by an I.Q. &lt;75.

          7. Exposure to dopamine receptor antagonists within the previous three (3) months.

          8. Exposure to radiopharmaceuticals within four (4) weeks prior to PET scan.

          9. Subjects receiving psychotropic medication.

         10. Any clinically significant abnormality in the screening laboratory tests, vital signs,
             or 11-lead ECG, outside of normal limits.

         11. Any woman of childbearing potential who is seeking to become pregnant or suspects that
             she may be pregnant.

         12. Subjects with a known recent history (within the past six (6) months) of illicit drug
             or alcohol dependence.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Spencer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Cambridge</city>
        <state>Massachusetts</state>
        <zip>02138</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://massgeneral.org/pediatricpsych/home.html</url>
  </link>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 28, 2007</study_first_submitted>
  <study_first_submitted_qc>January 11, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2008</study_first_posted>
  <results_first_submitted>February 15, 2011</results_first_submitted>
  <results_first_submitted_qc>May 11, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 10, 2011</results_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 13, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Thomas J. Spencer, MD</investigator_full_name>
    <investigator_title>Associate Chief, Clinical and Research Program, Pediatric Psychopharmacology</investigator_title>
  </responsible_party>
  <keyword>Adults</keyword>
  <keyword>Healthy Volunteers</keyword>
  <keyword>Nuvigil</keyword>
  <keyword>Armodafinil</keyword>
  <keyword>DAT occupancy in healthy volunteers</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Armodafinil</mesh_term>
    <mesh_term>Modafinil</mesh_term>
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Dopamine Agonists</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Twelve healthy human subjects between 18 and 55 years old were sequentially recruited from advertisements.</recruitment_details>
      <pre_assignment_details>12 healthy human subjects were enrolled and completed the study. Enrollment was gender-balanced. Six subjects (3 males, 3 females) were be randomly assigned to the C-11 altropane group; six subjects (3 males, 3 females) were be randomly assigned to the C-11 raclopride group, all in an open-label protocol.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Armodafinil (100mg)</title>
          <description>One 100 mg orally administered dose of Armodafini before PET scan.</description>
        </group>
        <group group_id="P2">
          <title>Armodafinil (250mg)</title>
          <description>One 250 mg orally administered dose of Armodafini before PET scan.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Armodafinil (100mg)</title>
          <description>One 100 mg orally administered dose of Armodafini before PET scan.</description>
        </group>
        <group group_id="B2">
          <title>Armodafinil (250mg)</title>
          <description>One 250 mg orally administered dose of Armodafini before PET scan.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25.13" spread="1.1" lower_limit="22.83" upper_limit="34.5"/>
                    <measurement group_id="B2" value="21.44" spread="2.5" lower_limit="18.75" upper_limit="22.92"/>
                    <measurement group_id="B3" value="23.29" lower_limit="18.75" upper_limit="34.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Armodafinil DAT Occupancy in Caudate</title>
        <description>Subjects received each dose level (100 and 250 mg) of armodafinil, followed by PET scans, in an open-label protocol. Repeat PET scans, using [1 1 C]altropane, determined DAT occupancy at 1 hour and 2.5 hours postdose (compared with baseline).</description>
        <time_frame>DAT occupancy was measured using the PET scan at 1 hour and 2.5 hours after oral administration of 100mg or 250 mg Armodafinil</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil (100mg)</title>
            <description>One 100 mg orally administered dose of Armodafini before PET scan.</description>
          </group>
          <group group_id="O2">
            <title>Armodafinil (250mg)</title>
            <description>One 250 mg orally administered dose of Armodafini before PET scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Armodafinil DAT Occupancy in Caudate</title>
          <description>Subjects received each dose level (100 and 250 mg) of armodafinil, followed by PET scans, in an open-label protocol. Repeat PET scans, using [1 1 C]altropane, determined DAT occupancy at 1 hour and 2.5 hours postdose (compared with baseline).</description>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>1 Hour</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="9.0"/>
                    <measurement group_id="O2" value="60.5" spread="7.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>2.5 hours</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.4" spread="9.5"/>
                    <measurement group_id="O2" value="65.2" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (With Outlier)</title>
        <description>Each subject received each dose level (one dose per day of 100 or 250 mg) of armodafinil, followed by PET scans using [11C]raclopride, to determine the change in extracellular dopamine at 2.5 hours postdose.</description>
        <time_frame>Extracellular DAT was measured using the PET scan at 2.5 hours after oral administration of 100mg or 250 mg Armodafinil on three different study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil (100mg)</title>
            <description>One 100 mg orally administered dose of Armodafini before PET scan.</description>
          </group>
          <group group_id="O2">
            <title>Armodafinil (250mg)</title>
            <description>One 250 mg orally administered dose of Armodafini before PET scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (With Outlier)</title>
          <description>Each subject received each dose level (one dose per day of 100 or 250 mg) of armodafinil, followed by PET scans using [11C]raclopride, to determine the change in extracellular dopamine at 2.5 hours postdose.</description>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.8" spread="30.1"/>
                    <measurement group_id="O2" value="7.0" spread="8.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (Without Outlier)</title>
        <description>Each subject received each dose level (one dose per day of 100 or 250 mg) of armodafinil, followed by PET scans using [11C]raclopride, to determine the change in extracellular dopamine at 2.5 hours postdose.</description>
        <time_frame>Extracellular DAT was measured using the PET scan at 2.5 hours after oral administration of 100mg or 250 mg Armodafinil on three different study visits</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Armodafinil (100mg)</title>
            <description>One 100 mg orally administered dose of Armodafini before PET scan.</description>
          </group>
          <group group_id="O2">
            <title>Armodafinil (250mg)</title>
            <description>One 250 mg orally administered dose of Armodafini before PET scan.</description>
          </group>
        </group_list>
        <measure>
          <title>Armodafinil Extracellular Dopamine in Caudate at 2.5 Hours (Without Outlier)</title>
          <description>Each subject received each dose level (one dose per day of 100 or 250 mg) of armodafinil, followed by PET scans using [11C]raclopride, to determine the change in extracellular dopamine at 2.5 hours postdose.</description>
          <units>μg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.0" spread="9.4"/>
                    <measurement group_id="O2" value="5.3" spread="8.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Armodafinil (100mg)</title>
          <description>One 100 mg orally administered dose of Armodafini before PET scan.</description>
        </group>
        <group group_id="E2">
          <title>Armodafinil (250mg)</title>
          <description>One 250 mg orally administered dose of Armodafini before PET scan.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle soreness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>shoulder pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>slightly jittery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>hyperactivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>cold/ congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Extracellular dopamine could compete with [11C] altropane, causing an overestimation of DAT occupancy. Time between scans and menstrual cycle could be sources of variability. Brain pathology although unlikely in normal subjects, is possible.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Thomas J. Spencer, MD</name_or_title>
      <organization>Massachusetts General Hospital; Harvard Medical School</organization>
      <phone>(617) 726-1731</phone>
      <email>tspencer@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

